Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The objective of this Investigation is to evaluate the safety and efficacy of long-term
treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse
drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey
period, and whether an additional treatment outcome investigation and/or a post-marketing
clinical study is required in the future will be determined.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.